Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Immutep (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company focused on developing LAG-3 immunotherapies for cancer and autoimmune diseases, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Marc Voigt, will engage in a fireside chat on Wednesday, October 16, 2024, at 9:30 am ET.
The event will be streamed live on M-Vest, and interested parties can reserve their seats through a provided link. This participation underscores Immutep's commitment to engaging with the investment community and sharing insights about their innovative immunotherapy research and development efforts.
Immutep (ASX: IMM; NASDAQ: IMMP), un'azienda biotecnologica in fase clinica impegnata nello sviluppo di immunoterapie LAG-3 per il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. L'amministratore delegato dell'azienda, Marc Voigt, parteciperà a una chiacchierata informale mercoledì 16 ottobre 2024, alle 9:30 ET.
L'evento sarà trasmesso in diretta su M-Vest, e le parti interessate possono riservare i loro posti tramite un link fornito. Questa partecipazione sottolinea l'impegno di Immutep nel coinvolgere la comunità degli investitori e nel condividere intuizioni sui loro sforzi innovativi nella ricerca e nello sviluppo di immunoterapie.
Immutep (ASX: IMM; NASDAQ: IMMP), una empresa biotecnológica en etapa clínica centrada en el desarrollo de inmunoterapias LAG-3 para el cáncer y enfermedades autoinmunes, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. El director ejecutivo de la empresa, Marc Voigt, participará en una charla informal el miércoles 16 de octubre de 2024, a las 9:30 am ET.
El evento se transmitirá en vivo a través de M-Vest, y las partes interesadas pueden reservar sus asientos a través de un enlace proporcionado. Esta participación resalta el compromiso de Immutep con la comunidad de inversores y la compartición de información sobre sus innovadoras investigaciones y desarrollos en el campo de la inmunoterapia.
Immutep (ASX: IMM; NASDAQ: IMMP)는 암 및 자가면역 질환을 위한 LAG-3 면역요법 개발에 중점을 두고 있는 임상 단계 생명공학 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 회사의 CEO인 Marc Voigt는 2024년 10월 16일 수요일, 오전 9:30 ET에 대화에 참여할 예정입니다.
이 행사는 M-Vest에서 실시간으로 스트리밍되며, 관심 있는 분들은 제공된 링크를 통해 자리를 예약할 수 있습니다. 이번 참여는 투자 커뮤니티와의 소통 및 혁신적인 면역요법 연구 및 개발 노력에 대한 통찰을 공유하겠다는 Immutep의 의지를 강조합니다.
Immutep (ASX: IMM; NASDAQ: IMMP), une entreprise de biotechnologie en phase clinique axée sur le développement des immunothérapies LAG-3 pour le cancer et les maladies auto-immunes, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG de l'entreprise, Marc Voigt, participera à une discussion informelle le mercredi 16 octobre 2024, à 9h30 ET.
L'événement sera diffusé en direct sur M-Vest, et les parties intéressées peuvent réserver leurs places via un lien fourni. Cette participation souligne l'engagement d'Immutep à s'engager avec la communauté des investisseurs et à partager des informations sur leurs efforts innovants en matière de recherche et de développement d'immunothérapies.
Immutep (ASX: IMM; NASDAQ: IMMP), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von LAG-3-Immuntherapien für Krebs und Autoimmunerkrankungen konzentriert, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Der CEO des Unternehmens, Marc Voigt, wird am Mittwoch, den 16. Oktober 2024, um 9:30 Uhr ET in einem Fireside-Chat teilnehmen.
Die Veranstaltung wird live auf M-Vest gestreamt, und interessierte Parteien können ihre Plätze über einen bereitgestellten Link reservieren. Diese Teilnahme unterstreicht das Engagement von Immutep, mit der Investmentgemeinde in Kontakt zu treten und Einblicke in ihre innovativen Forschungs- und Entwicklungsanstrengungen im Bereich der Immuntherapie zu teilen.
- None.
- None.
Media Release
SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will participate in a fireside chat at the Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 9:30 am ET.
The fireside chat will be live on M-Vest. Click here to reserve your seat.
About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
When is Immutep (IMMP) participating in the 2024 Maxim Healthcare Virtual Summit?
What type of immunotherapies is Immutep (IMMP) developing?
How can investors watch Immutep's (IMMP) fireside chat at the Maxim Healthcare Virtual Summit?
What is the focus of Immutep's (IMMP) presentation at the 2024 Maxim Healthcare Virtual Summit?
